NFKB1 and cancer: The application of a specific pharmacologic NF‐κB inhibitor, BAY 11‐7082, significantly prevents the transcriptional activation of the acidic bile‐induced cancer‐related mRNA phenotype, suggesting a possible role of NF‐κB as a key mediator of acidic bile‐stimuli and early molecular oncogenic events in treated human hypopharyngeal epithelial cells.15, 16, 17